An advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on February 9 recommended approval for Shionogi’s naldemedine, a novel peripherally-acting mu-opioid receptor antagonist. The Pharmaceutical Affairs and Food Sanitation Council’s First Committee on Drugs, a de-facto decision-making…
To read the full story
Related Article
- MHLW Approves Ninlaro, Intuniv, Other Drugs
March 31, 2017
REGULATORY
- Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





